IP Library Granted Patent US 11,587,694
Granted Patent B2
US 11,587,694 · App. 16/816,822 · Granted Feb 21, 2023

Methods of isolating radioactive mercury and uses thereof

Inventors: John Despotopulos (Livermore, CA); Carlos Valdez (San Ramon, CA); Kelly Nora Kmak (Berkeley, CA)
Assignee: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
G21G1/001A61N5/1001G21G4/08A61N2005/1019G21G2001/0094
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,587,694
App. No.
16/816,822
Granted
Feb 21, 2023
Kind
B2
Abstract

Provided herein are methods of isolating and using radioactive mercury. In particular, provided herein are methods of isolating radioactive mercury including the use of a thiacrown ether, and using the isolated radioactive mercury in therapeutic and/or imaging applications.

Claims (26)

1. A method of isolating radioactive mercury comprising:

extracting the radioactive mercury from an aqueous solution with an organic solution comprising thiacrown ether to form an extracted solution; and,

isolating the radioactive mercury from the extracted solution.

2. The method of claim 1 , wherein the radioactive mercury comprises 197m Hg, 197g Hg, or a combination thereof.

3. The method of claim 1 , wherein the thiacrown ether comprises dibenzohexathia-18-crown-6 ether, 1,4,7,10,13,16-hexathiacyclooctadecane, (2Z,5Z,8Z,11Z,14Z,17Z)-1,4,7,10,13,16-hexathiacyclooctadeca-2,5,8,11,14,17-hexaene, or a combination thereof.

4. The method of claim 3 , wherein the thiacrown ether comprises dibenzohexathia-18-crown-6 ether.

5. The method of claim 1 , wherein the aqueous solution has an acid concentration of less than 1 M.

6. The method of claim 5 , wherein the aqueous solution comprises nitric acid, hydrochloric acid, or a combination thereof.

7. The method of claim 1 , wherein the isolating comprises admixing the extracted solution and a strong acid to extract the radioactive mercury from the extracted solution, wherein the strong acid is selected from the group consisting of hydrochloric acid, nitric acid, hydrobromic acid, hydroiodic acid, and any combination thereof.

8. The method of claim 7 , wherein the strong acid has a concentration of at least 1.5 M.

9. The method of claim 7 , wherein the strong acid has a concentration of at least 6 M.

10. The method of claim 1 , wherein the radioactive mercury is prepared by irradiating platinum foil with alpha particles to form the radioactive mercury.

11. The method of claim 10 , wherein the alpha particles have a kinetic energy of 20 MeV to 25 MeV.

12. The method of claim 1 , wherein the radioactive mercury is prepared by irradiating gold foil with protons to form the radioactive mercury.

13. The method of claim 12 , wherein the protons have a kinetic energy of 10 MeV to 15 MeV.

14. The method of claim 1 , wherein the method is carried out in one hour or less.

15. The method of claim 1 , wherein the radioactive mercury is no-carrier-added 197m,g Hg.

16. A pharmaceutical composition comprising the radioactive mercury isolated according to the process of claim 1 and a pharmaceutically acceptable carrier, wherein the radioactive mercury comprises 197g Hg.

17. A method comprising

extracting radioactive mercury from an aqueous solution with an organic solution comprising thiacrown ether to form an extracted solution;

isolating the radioactive mercury from the extracted solution; and,

administering the radioactive mercury to a subject.

18. The method of claim 17 , wherein the radioactive mercury comprises 197m Hg and the method further comprises subjecting the subject to an imaging modality.

19. The method of claim 18 , wherein the imaging modality is selected from the group consisting of positron emission tomography (PET), positron emission tomography/computed tomography (PET/CT), positron emission tomography/magnetic resonance imaging (PET/MRI), single-photon emission computerized tomography (SPECT), and single-photon emission computerized tomography/computed tomography (SPECT/CT).

20. The method of claim 17 , wherein the radioactive mercury comprises 197g Hg and the radioactive mercury is administered in a therapeutically effective amount.

21. The method of claim 17 , wherein the subject suffers from cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2021
From: DESPOTOPULOS, JOHN; VALDEZ, CARLOS; KMAK, KELLY NORA
To: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
Reel/Frame 054936/0789 →
CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS) Recorded Jul 29, 2020
From: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
To: U.S. DEPARTMENT OF ENERGY
Reel/Frame 053350/0217 →
Continuity (1)
Related Publication 20210287822A1 · Sep 16, 2021